NanoViricides, Inc. Company Profile

News Articles [ 82 Associated News Articles listed on BioPortfolio]

[NanoViricides] brings in $6mm via PIPE

[NanoViricides Inc.] has raised $6mm through the private sale of four-year 8% unsecured convertible debentures and three-year warrants priced at $1 to three undisclosed returning shareholders and an u...

NanoViricides reports stronger cash position; sufficient for first clinical trials

NanoViricides (OTCBB:NNVC), a development stage company creating special purpose nanomaterials for antiviral therapy, said Wednesday its cash position at the end of the first quarter was "suffici...

NanoViricides Reports That Oral Administration of FluCide, its Anti-Influenza Drug Candidate Was Effective In Animal Model

WEST HAVEN, Conn.--(BUSINESS WIRE)--Aug 13, 2012 - NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that an anti-influenza drug candidate under its FluCide™ program is effecti...

NanoViricides Reports That Oral Administration of FluCide Anti-Influenza Drug Candidates Led to Survival Improvements Comparable to IV Administration and Was Far Superior to Oseltamivir, in a Highly Lethal Animal Model

WEST HAVEN, Conn.--(BUSINESS WIRE)--Aug 20, 2012 - NanoViricides, Inc. (OTCBB: NNVC) (the "Company") announced today that anti-influenza drug candidates under its FluCide™ program, when given o...

NanoViricides, Inc. Reports Oral FluCide Is Highly Effective Against H3N2 Influenza A Virus and Superior to Tamiflu based on Increased Survival in a Lethal Influenza Animal Model

WEST HAVEN, Conn.--(BUSINESS WIRE)--Sep 24, 2012 - NanoViricides, Inc. (OTCBB: NNVC) (the "Company") reported today that its oral FluCide™ drug candidates demonstrated dramatically improved sur...

NanoViricides' flu drug candidates demonstrate oral effectiveness

US drug developer NanoViricides (OTCBB: NNVC) says that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections. Two...

NanoViricides Reports that Oral Administration of FluCide Anti-Influenza Drug Candidates Caused Lung Viral Load Decrease Comparable to IV Administration and Far Superior to Oseltamivir, in a Highly Lethal Animal Model

WEST HAVEN, Conn.--(BUSINESS WIRE)--Aug 27, 2012 - NanoViricides, Inc. (OTCBB: NNVC) (the "Company") announced today that anti-influenza drug candidates under its FluCide™ program, when given or...

NanoViricides Reports Its Oral FluCide Anti-Influenza Drug Candidates Are Superior to Oral Oseltamivir (TamiFlu) in H1N1 Influenza Lethal Infection Model

WEST HAVEN, Conn.--(BUSINESS WIRE)--September 10, 2012 07:00 AM Eastern Daylight Time--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that oral administration of its FluCide™...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [ 2 Associated Companies listed on BioPortfolio]

NanoViricides, Inc.

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricid...

Alliance for Biosecurity

The Alliance for Biosecurity was formed in June of 2005 by biopharmaceutical companies and the Center for Biosecurity of the University of Pittsburgh Medical Center. Alliance members are committed to...